Ligand id: 6584

Name: abciximab

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: abciximab

Compound class Antibody
Approved drug? Yes (FDA (1994))
International Nonproprietary Names
INN number INN
7200 abciximab
7E3 antibody | antiGPIIBIIIa | C7E3 | ReoPro®
Abciximab is a chimeric human-murine monoclonal antibody Fab (fragment antigen binding) fragment designed to target glycoprotein IIb/IIIa receptor, a key mediator of platelet aggregation and clot formation [2]. The invention of abciximab is covered by patent US5976532 [1], where its originating antibody is coded c7E3.
Database Links
Specialist databases
IMGT/mAb-DB 146
Other databases
GtoPdb PubChem SID 178103197
PubChem SID 178103197
Search PubMed clinical trials abciximab
Search PubMed titles abciximab
Search PubMed titles/abstracts abciximab
Wikipedia Abciximab